Royalty Report: Medical, Device, Supply – Collection: 5286

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Medical
  • Device
  • Supply
  • Surgical
  • Wound Care
  • Technical Know How
  • Tissue

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5286

License Grant
Under our license agreements, the Licensee has exclusive rights to manufacture, market and distribute all current and future sizes of the patented Angio-Seal for hemostatic puncture closures for cardiovascular use worldwide.
License Property
Angio-Seal(TM) Vascular Closure Device (Angio-Seal) is designed to seal and close femoral artery punctures made during diagnostic and therapeutic cardiovascular catheterizations.  The Angio-Seal STS Plus device offers quick, consistent and predictable hemostasis (cessation of bleeding) at the puncture site. Its fast, secure closure reduces the risk of complications and can allow patients to resume activities sooner than if managed with manual compression.  The Angio-Seal STS Plus device includes a small bio-resorbable anchor, suture and collagen pad. The anchor is placed in the artery through a small delivery system and secured against the artery's interior wall. Then the collagen pad, which is positioned on the outside of the artery, is bound together with the suture to form a secure seal. The self-tightening suture enables the physician to finalize the closure procedure immediately. Unlike many other vascular closure devices, all components of the Angio-Seal STS Plus device are fully absorbed with 60 to 90 days, so no foreign material permanently remains in the body.  The angio-Seal STS plus platform is composed of an absorbable collagen sponge and a specially designed absorbable polymer anchor connected by an absorbable self-tightening suture. The device seals and sandwiches the arteriotomy between its two primary components, the anchor and the collagen sponge. Hemostasis is achieved primarily through mechanical means and is supplemented by the platelet inducing properties of the collagen.
Field of Use
The rights granted apply for hemostatic puncture closures for cardiovascular use.

IPSCIO Record ID: 289220

License Grant
Licensor grants, under Licensor’s and each of its Affiliates’ respective rights in the Licensed Patents, a non-exclusive, non-transferable, worldwide, irrevocable, perpetual license to make, have made, use, import, export, market, sell, have sold, offer for sale, distribute and otherwise exploit Royalty-Bearing Products within the Orthopedic Field.

The Parties agree to promptly dismiss all claims and counter-claims with this agreement.

License Property
Royalty-Bearing Products means the Accused Products, the Non-Accused Products and any New Product or Other Product that Licensee elects to be a Royalty-Bearing Product; each of the foregoing solely to the extent the manufacture, use, sale, offering for sale, importation, exportation or other exploitation of which in a particular country would, in the absence of the licenses, covenants, releases and immunities granted by Licensor under this Agreement, infringe, contribute to the infringement of, or induce the infringement of any Valid Claim of any patent within the Licensed Patents issued in such country.

The accused products are Magnum I, Magnum II, and, Mini-Magnum.

The patents relate to Suture anchor, Bone suture, Body tissue fastening, Method of positioning body tissue relative to a bone, and, Method and apparatus for use in anchoring a suture.

Field of Use
Orthopedic Field means the branch of medicine that deals with the diagnosis, analysis, treatment, prevention, correction, rehabilitation or study of injuries or disorders of the skeletal system and associated muscles, joints and ligaments.

IPSCIO Record ID: 260430

License Grant
Licensor grants the exclusive license to Manufacture, use and Distribute Products for Permitted Clinical Applications within the Territory. All Products must be Manufactured using Modified Starch at a Licensee Facility in the United States or at any Licensee Facility outside of the United States approved by Licensor in writing.

For the Manufacturing IP, Licensor shall deliver to Licensee all documents, memoranda, schematics, diagrams and other information (whether in written, electronic or other form) disclosing and describing all methods and processes necessary or useful for Manufacturing the Products using Modified Starch

License Property
Licensor has the exclusive right to create biocompatible, absorbable polysaccharides using the AMPâ„¢ technology.

The patent is Modified Starch Material of Biocompatible Hemostasis.

PerClot(R) is a novel polysaccharide hemostatic agent used in surgery.  PerClot is a medical device composed of absorbable modified polymer (AMP(R)) particles and delivery applicators. AMP particles are derived from purified plant starch. PerClot contains no human or animal components. It is intended for use as an absorbable hemostatic system to control bleeding during surgical procedures or following traumatic injuries.

Field of Use
All permitted indications for use of the Products obtained by Licensor that are for class III medical devices as of the Effective Date of this Agreement (whether such indications could be downgraded or modified in the future to be for class I or class II medical devices). Such permitted indications include use in surgical procedures or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.
Contra-indications specified in the PerClot IFU are not Permitted Clinical Applications.  Notwithstanding the foregoing, Permitted Clinical Applications do not include topical hemostasis, first aid, woundcare, all non-absorbable hemostatic applications ( defined as class I or class II medical device) and anti-adhesion applications.

PerClot is a unique, absorbable powder hemostat that is indicated for use in surgical procedures, including cardiac, vascular, orthopedic, spinal, neurological, gynecological, ENT and trauma surgery as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.

IPSCIO Record ID: 26781

License Grant
Licensor, who shares an operating officer with Licensee, hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory. Such license shall be exclusive within the Territory in the Field of Use.  All Fields of Use, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.
License Property
This agreement is related to U.S. Pat. No. 5,941,897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.

This is technology where the arteriotomy can be sealed by delivery of a patient specific autologous fibrin glue to a debrided, synthesized area adjacent to the extravascular opening of the arteriotomy.

Field of Use
All FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.

IPSCIO Record ID: 294278

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license in the Territory, bearing royalties as set forth in this Agreement, with the right to grant sublicenses, under the Licensor Patents, Licensor Know-How and Other Licensor IP, to make, have made, use, sell, offer for sale and import Products for use solely in the Field and in the Territory.
License Property
PFO is a medical device known as the PFO Closure Device for use in patent foramen ovale.

Licensor Patents means a Patent that (a) claims the Product or any component thereof, or any other method, apparatus, material or article of manufacture useful in the development, manufacture, use or sale of Product, and (b) is Controlled by Licensor.

Product means the PFO Closure Device developed under this Agreement and described in the Device Description and Sequence of Operation as set forth.  The PFO closure device is intended to close a heart abnormality – the patent foreman ovale (PFO).

Patent means (a) unexpired United States and foreign patents, including without limitation any substitution, extension, registration, confirmation, reissue, re-examination, renewal of such patents and (b) pending applications for such patents, including without limitation any continuation, divisional or continuation-in-part thereof and any provisional applications.

A PFO closure device is moved through the vein to the heart, and specifically to the location of the heart wall defect. Once in the correct location, the PFO closure device is formed so that it straddles each side of the hole. The device will remain in the heart permanently to stop the abnormal flow of blood between the two atrial chambers of the heart. The catheter is then removed and the procedure is complete.

Field of Use
The Vascular Access Closure Device is an innovative automated system designed to close access openings in femoral arteries after interventional vascular procedures.

IPSCIO Record ID: 5234

License Grant
Licensee wishes to grant Licensor, an individual, a bonus pursuant to Licensee's obligations under its Employment Agreement with Licensor dated April 1, 1999, all upon the terms and conditions set forth.
License Property
The first Patent # 5,486,195 was for the Method and Apparatus for Arteriotomy Closure. The second Patent # 5,941,897 was for the Energy Activated Fibrin Plug.  The Myers Solution is a puncture closing product and technique that utilizes a human glue deployment to close puncture wounds following surgery, thereby avoiding sutures and limiting discomfort to patients following surgery.
Field of Use
The rights granted apply to puncture wounds.

IPSCIO Record ID: 369243

License Grant
For the CoSeal Sealant Units Exclusive Distribution, Sales and Marketing Rights,  Licensors of the United States, Switzerland and Canada grant
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory during the term of this Distribution and License Agreement.

For the CoSeal Sealant Option, Licensor grants an option (the CoSeal Sealant Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan.

For the CoSeal Adhesion Prevention Units Exclusive Distribution, Sales and Marketing Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory during the term of this Distribution and License Agreement.

For the CoSeal Adhesion Prevention Option, Licensor grants to an option (the CoSeal Adhesion Prevention Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States.

For the CoSeal Accessories Exclusive Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Accessories in the Field in the Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import the CoSeal Accessories in the Field in the Territory.

License Property
The trademarks include COSEAL©, ADHIBIT™, and, ANGIOTECHKNOWLEDGY™.

CoSeal Ingredients shall mean the two derivatized polyethylene glycol ingredients, designated COH102 and COH206

CoSeal Adhesion Prevention Unit shall mean a CoSeal Adhesion Prevention Product sold in combination with a CoSeal Adhesion Prevention Device.

CoSeal Devices shall mean, collectively, as the context requires, both or either of the CoSeal Adhesion Prevention Devices and/or the CoSeal Sealant Devices.

CoSeal Unit shall mean, collectively, as the context requires, both or either of the CoSeal Sealant Unit and/or the CoSeal Adhesion Prevention Unit.

CoSeal Sealant Unit shall mean a CoSeal Sealant Product sold in combination with a CoSeal Sealant Device.

CoSeal Sealant Product shall mean a product containing the CoSeal Ingredients that is the subject matter of a Regulatory Filing for use as a tissue sealant, adhesive or glue, has been or is approved by one or more Regulatory Authorities for use as a tissue sealant, adhesive or glue, or that is in development or sold for use as a tissue sealant, adhesive or glue.

Field of Use
CoSeal is indicated for use in vascular reconstructions to achieve adjunctive ·hemostasis by mechanically sealing areas of leakage.  CoSeal is designed to rapidly seal tissue surfaces, suture lines and synthetic grafts during surgery.

Field shall mean human therapeutic use for any and all tissue sealing, adhesive, glue or adhesion prevention barrier indications but shall specifically exclude any use (i) in Hemostat indications; (ii) for tissue regeneration indications; (iii) as an osteobiologic for skeletal repair an non-pharmacologic devices for osteoarthritis treatment,; (iv) as a urinary incontinence product and for the treatment of urinary incontinence; or (v) as an ostomy product.

IPSCIO Record ID: 29043

License Grant
Licensor hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory.
License Property
The agreement relates to U.S. Pat. No. 5,594,1897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.
Field of Use
FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.

IPSCIO Record ID: 2171

License Grant
Under an agreement, the Company transferred the license agreement to a patented modified collagen hemostatic sponge for use to control bleeding in vascular and general surgery.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.